Haemoctin Sdh

Haemoctin Sdh is a plasma‑derived human coagulation factor VIII concentrate provided as a sterile solution for injection. The product contains human factor VIII and is given intravenously by prescription. It is marketed in the European Union as a hemostatic agent for replacing deficient factor VIII in patients with bleeding disorders, including treatment of acute bleeds and prophylaxis in hemophilia A and may be used under specialist supervision in clinical practice.

Haemoctin Sdh is used to replace deficient factor VIII in patients with hemophilia A and related bleeding disorders.

- Treatment of acute bleeding episodes in individuals with congenital hemophilia A. - On‑demand therapy for breakthrough bleeds in patients receiving prophylaxis. - Management of surgical or invasive procedures requiring hemostasis in hemophilia A. - Treatment of acquired hemophilia A caused by autoantibodies against factor VIII. - Prophylactic routine infusion to reduce the frequency of spontaneous joint and muscle bleeds. - Adjunctive use with bypassing agents in patients with inhibitors when factor VIII activity is partially restored.

The safety profile of Haemoctin Sdh reflects observations typical for plasma‑derived factor VIII products.

Common: - Mild headache or fatigue. - Low‑grade fever. - Localized infusion site reactions such as erythema or mild swelling. - Transient increase in liver enzymes. - Transient nausea or vomiting. - Mild arthralgia. - Mild dizziness. - Transient increase in blood pressure. - Mild flushing.

Serious: - Development of inhibitors (neutralizing antibodies) against factor VIII. - Anaphylactic or severe allergic reactions, including urticaria and bronchospasm. - Thromboembolic events, such as deep‑vein thrombosis or pulmonary embolism. - Transmission of blood‑borne pathogens (theoretical risk despite viral inactivation). - Renal impairment related to infusion volume. - Severe hemolysis (rare). - Immune complex-mediated vasculitis (very rare). - Severe disseminated intravascular coagulation (extremely rare).

When prescribing Haemoctin Sdh, clinicians should consider several precautionary measures to ensure safe use.

- Assess patient history for prior development of factor VIII inhibitors before initiating therapy. - Perform viral safety screening and confirm product integrity, especially for patients with compromised immune systems. - Monitor for signs of allergic reactions during and after infusion, and be prepared to manage anaphylaxis. - Evaluate thrombotic risk factors, such as recent surgery, immobilization, or a history of clotting disorders. - Adjust dosing in patients with renal or hepatic impairment, as clearance may be altered. - Use caution in pregnant or breastfeeding women; limited data are available regarding safety.

Haemoctin Sdh may interact with other agents that affect hemostasis or immune response.

Avoid: - Concomitant use of other plasma‑derived clotting factor concentrates without appropriate monitoring, as this may increase thrombotic risk. - Administration of bypassing agents (e.g., activated prothrombin complex concentrate) in patients without documented inhibitors, due to additive pro‑coagulant effects.

Use with caution: - Antifibrinolytic drugs such as tranexamic acid; monitor for excessive clot formation. - Immunosuppressive therapies (e.g., rituximab) that may alter inhibitor development; observe inhibitor titres. - High‑dose vitamin K therapy; assess coagulation parameters as vitamin K can affect other clotting factors. - Concurrent use of investigational gene‑therapy products for hemophilia; coordinate care to avoid overlapping factor replacement.